SRRK on Nasdaq
Scholar Rock Holding Corp
In its 2026 annual report the company says: “We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy and additional rare, severe and debilitating neuromuscular diseases. Our lead pipeline product candidates include apitegromab, a subcutaneous formulation of apitegromab, and SRK-439.”6 It is headquartered in Cambridge, United States.2 Its shares trade on Nasdaq under the symbol SRRK.2
$40.78 up 1.18 (2.98%)Price as of Oct 15, 2026 at 17:33 UTC
Last updated Oct 21, 2026.
Overview
Compare with Precision BioSciences, X4 Pharmaceuticals, Inc or C4 Therapeutics (United States), or pick any stock.
- TickerSRRK on Nasdaq2
- IndustryBiological Products, (No Diagnostic Substances)2
- HeadquartersCambridge, United States2
- Incorporated inDE4
- Business address301 Binney Street, 3Rd Floor, Cambridge, Ma 021424
- Filer categoryNon-accelerated filer4
- Legal formCorporation2
- LEI549300Z1FLPGL4OWJ4592
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressCORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 66674512
See how the biggest companies compare on our leaderboards
We are a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (“SMA”) and additional rare, severe and debilitating neuromuscular diseases. As a leader in the biology of the transforming growth factor beta (“TGFβ”) superfamily, our novel understanding of the molecular mechanisms of growth factor activation enabled the development of a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. Based on our innovative, proprietary, and scalable technology platform, we are building a world-leading anti-myostatin pipeline. During 2025, we made significant progress in advancing our product candidates. We believe 2026 could be a transformational year for Scholar Rock as we anticipate the potential to become a commercial-stag…6 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $208.4M | $184.6M |
| General and administrative | $176.2M | $67.5M |
| Total operating expenses | $384.6M | $252.1M |
| Loss from operations | -$384.6M | -$252.1M |
| Interest income | $13.9M | $12.7M |
| Interest expense | -$6.9M | -$6.8M |
| Other expense, net | -$301.0K | -$85.0K |
| Total other income (expense), net | $6.7M | $5.8M |
| Net loss per share, basic (in dollars per share) | -$3.29 | -$2.47 |
| Net loss per share, diluted (in dollars per share) | -$3.29 | -$2.47 |
| Weighted average common shares outstanding, basic (in shares) | 114.7M shares | 99.8M shares |
| Weighted average common shares outstanding, diluted (in shares) | 114.7M shares | 99.8M shares |
| Net loss | -$377.9M | -$246.3M |
| Unrealized gain (loss) on marketable securities | -$64.0K | $68.0K |
| Foreign currency translation adjustments | -$2.0K | |
| Total other comprehensive income (loss) | -$66.0K | $68.0K |
| Comprehensive loss | -$378.0M | -$246.2M |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 5 fiscal years (annual) or 5 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $323.5M | $177.9M | |||
| Marketable securities | $44.0M | $259.4M | |||
| Prepaid expenses and other current assets | $17.6M | $13.9M | |||
| Total current assets | $385.1M | $451.2M | |||
| Property and equipment, net | $1.7M | $2.8M | |||
| Operating lease right-of-use asset | $10.4M | $15.6M | |||
| Restricted cash | $3.8M | $2.4M | |||
| Other long-term assets | $3.2M | $2.9M | |||
| Total assets | $404.3M | $474.9M | |||
| Accounts payable | $10.3M | $10.1M | |||
| Accrued expenses | $39.6M | $31.1M | |||
| Operating lease liability | $5.5M | $5.8M | |||
| Total current liabilities | $55.4M | $46.9M | |||
| Long-term portion of operating lease liability | $3.7M | $9.2M | |||
| Long-term debt | $99.7M | $50.1M | |||
| Total liabilities | $158.8M | $106.3M | |||
| Common stock, $0.001 par value; 300,000,000 shares authorized; 108,461,354 and 93,823,678 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $108.0K | $94.0K | |||
| Additional paid-in capital | $1.5B | $1.3B | |||
| Accumulated other comprehensive income | $94.0K | $160.0K | |||
| Accumulated deficit | -$1.3B | -$922.7M | |||
| Total stockholders' equity | $245.5M | $368.6M | $225.2M | ||
| Total liabilities and stockholders' equity | $404.3M | $474.9M | |||
| Preferred stock, par value | $0.00 | $0.00 | |||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |||
| Preferred stock, shares issued | 0 shares | 0 shares | |||
| Preferred stock, shares outstanding | 0 shares | 0 shares | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | 300.0M shares | 150.0M shares | |
| Common stock, shares issued | 108.5M shares | 93.8M shares | |||
| Common stock, shares outstanding | 108.5M shares | 93.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 | 2024-05-31 | 2023-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | $323.5M | $177.9M | |||
| Marketable securities | $44.0M | $259.4M | |||
| Prepaid expenses and other current assets | $17.6M | $13.9M | |||
| Total current assets | $385.1M | $451.2M | |||
| Property and equipment, net | $1.7M | $2.8M | |||
| Operating lease right-of-use asset | $10.4M | $15.6M | |||
| Restricted cash | $3.8M | $2.4M | |||
| Other long-term assets | $3.2M | $2.9M | |||
| Total assets | $404.3M | $474.9M | |||
| Accounts payable | $10.3M | $10.1M | |||
| Accrued expenses | $39.6M | $31.1M | |||
| Operating lease liability | $5.5M | $5.8M | |||
| Total current liabilities | $55.4M | $46.9M | |||
| Long-term portion of operating lease liability | $3.7M | $9.2M | |||
| Long-term debt | $99.7M | $50.1M | |||
| Total liabilities | $158.8M | $106.3M | |||
| Common stock, $0.001 par value; 300,000,000 shares authorized; 108,461,354 and 93,823,678 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $108.0K | $94.0K | |||
| Additional paid-in capital | $1.5B | $1.3B | |||
| Accumulated other comprehensive income | $94.0K | $160.0K | |||
| Accumulated deficit | -$1.3B | -$922.7M | |||
| Total stockholders' equity | $245.5M | $368.6M | $225.2M | ||
| Total liabilities and stockholders' equity | $404.3M | $474.9M | |||
| Preferred stock, par value | $0.00 | $0.00 | |||
| Preferred stock, shares authorized | 10.0M shares | 10.0M shares | |||
| Preferred stock, shares issued | 0 shares | 0 shares | |||
| Preferred stock, shares outstanding | 0 shares | 0 shares | |||
| Common stock, par value | $0.00 | $0.00 | |||
| Common stock, shares authorized | 300.0M shares | 300.0M shares | 300.0M shares | 150.0M shares | |
| Common stock, shares issued | 108.5M shares | 93.8M shares | |||
| Common stock, shares outstanding | 108.5M shares | 93.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$377.9M | -$246.3M |
| Depreciation and amortization | $1.7M | $1.9M |
| Amortization of debt discount and debt issuance costs | $423.0K | $253.0K |
| Equity-based compensation | $75.6M | $36.6M |
| Amortization (accretion) of investment securities | -$4.0M | -$5.3M |
| Non-cash operating lease expense | $5.3M | $5.2M |
| Prepaid expenses and other current assets | -$3.7M | -$5.8M |
| Other assets | -$286.0K | $1.5M |
| Accounts payable | $208.0K | $6.6M |
| Accrued expenses | $8.5M | $10.5M |
| Operating lease liabilities | -$5.8M | -$6.3M |
| Net cash used in operating activities | -$300.0M | -$200.9M |
| Purchases of property and equipment | -$602.0K | -$98.0K |
| Purchases of marketable securities | -$98.0M | -$293.2M |
| Sales and maturities of marketable securities | $317.3M | $217.2M |
| Net cash provided by (used in) investing activities | $218.7M | -$76.1M |
| Proceeds from stock option exercises | $23.8M | $19.1M |
| Proceeds from pre-funded and common warrant exercises | $63.8M | $9.6M |
| Proceeds from sale of common shares and pre-funded warrants to purchase common shares, net | $91.7M | $324.4M |
| Proceeds from debt facility | $50.0M | |
| Debt modification payment | -$125.0K | |
| Proceeds from debt refinancing | $24.7M | |
| Payment of long-term debt | -$25.5M | |
| Net cash provided by financing activities | $228.4M | $353.0M |
| Net increase in cash, cash equivalents and restricted cash | $147.1M | $76.0M |
| Effect of exchange rate on cash, cash equivalents and restricted cash | -$2.0K | |
| Operating lease liability adjustment from rent modification | $9.5M | |
| Offering costs in accrued expenses | $314.0K | |
| Cash paid for interest | $6.1M | $6.6M |
No quarter-by-quarter statement was filed.
Corporate structure
Scholar Rock Holding Corp sits at the top of its group. 9 entities, 5 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Scholar Rock Holding Corp
- Redmile Group, LLC Filed SCHEDULE 13G/A on Scholar Rock Holding Corp, latest Aug 14, 2026 (9 filings since Feb 14, 2022)
- Invus Global Management, LLC Filed SCHEDULE 13G/A on Scholar Rock Holding Corp, latest Aug 13, 2026 (3 filings since Jul 29, 2024)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G/A on Scholar Rock Holding Corp, latest May 15, 2026 (7 filings since Feb 14, 2022)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Scholar Rock Holding Corp, latest Mar 27, 2026 (3 filings since Nov 4, 2024)
- Wellington Management Company Filed SCHEDULE 13G on Scholar Rock Holding Corp, latest Feb 10, 2026
- Samsara BioCapital, L.P. Filed SCHEDULE 13D/A on Scholar Rock Holding Corp, latest Oct 7, 2025 (4 filings since Feb 14, 2023)
- FMR LLC Filed SCHEDULE 13G/A on Scholar Rock Holding Corp, latest Feb 12, 2025 (5 filings since Feb 9, 2022)
- ORBIMED ADVISORS LLC Filed SC 13G/A on Scholar Rock Holding Corp, latest Nov 14, 2024 (2 filings since Feb 14, 2024)
- ARCH Venture Fund VIII, L.P. Filed SC 13G/A on Scholar Rock Holding Corp, latest Feb 14, 2024
- Artal International S.C.A. Filed SC 13G/A on Scholar Rock Holding Corp, latest Feb 9, 2024 (4 filings since Feb 11, 2022)
- Polaris Venture Partners VI, L.P. Filed SC 13G/A on Scholar Rock Holding Corp, latest Feb 9, 2024 (3 filings since Feb 11, 2022)
- BlackRock Filed SC 13G on Scholar Rock Holding Corp, latest Jan 26, 2024 (3 filings since Feb 3, 2022)
- Scholar Rock Holding Corp Cambridge, Massachusetts, United States
- Scholar Rock Foreign Holdings, Inc. Subsidiary · Delaware, United States
- Scholar Rock Germany GmbH Subsidiary · Germany
- Scholar Rock Ireland Limited Subsidiary · Ireland
- Scholar Rock Netherlands B.V. Subsidiary · Netherlands
- Scholar Rock Securities Corporation Subsidiary · Massachusetts, United States
- Scholar Rock Switzerland GmbH Subsidiary · Switzerland
- Scholar Rock U.S. Operations, Inc. Subsidiary · Delaware, United States
- Scholar Rock, Inc. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Scholar Rock Holding Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $16.6M7 Dec 31, 2025 | $16.0M7 Dec 31, 2024 | +3.8% |
| Accumulated depreciation | $14.9M7 Dec 31, 2025 | $13.2M7 Dec 31, 2024 | +12.5% |
| Property and equipment, net | $1.7M7 Dec 31, 2025 | $2.8M7 Dec 31, 2024 | −38.2% |
| Operating-lease assets (leased space) | $10.4M7 Dec 31, 2025 | $15.6M7 Dec 31, 2024 | −33.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $323.5M7 Dec 31, 2025 | $177.9M7 Dec 31, 2024 | +81.9% |
| Marketable securities, current | $44.0M7 Dec 31, 2025 | $259.4M7 Dec 31, 2024 | −83.0% |
| Debt securities available for sale | $44.0M7 Dec 31, 2025 | $259.4M7 Dec 31, 2024 | −83.0% |
Properties, in its own words
Our corporate headquarters and operations are located in Cambridge, Massachusetts.
In November 2019, we entered into a lease of laboratory and office space at 301 Binney Street in Cambridge, Massachusetts to be used as our new corporate headquarters. The expiration date was originally in August 2025 and included an option to extend the term by two years. In May 2024, we entered into the First Amendment to the Lease to extend the term for approximately two years, commencing on August 19, 2025 with an option to extend the term by five years.
The rest of Item 2
We believe that our existing facility is adequate to meet our current needs, and that suitable additional space will be available as and when needed.
Item 2 of the 10-K filed Mar 3, 2026.6
Leadership
Who has led Scholar Rock Holding Corp, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerDavid Hallal Apr 29, 2025 to now15
- Chief executive officerJay T. Backstrom Sep 22, 2022 to Mar 12, 202516
- Chief executive officerStuart A. Kingsley Jul 17, 2020 to Feb 3, 202117
- Chief executive officerNagesh K. Mahanthappa May 23, 2018 to Jun 21, 202218
- PresidentAkshay Vaishnaw Apr 29, 2025 to now19
- PresidentStuart A. Kingsley Jul 17, 2020 to Feb 3, 202117
- PresidentNagesh K. Mahanthappa May 23, 2018 to Jun 21, 202218
- Chief financial officerVikas Sinha Apr 29, 2025 to now20
- Chief financial officerEdward H. Myles Jul 17, 2020 to Mar 12, 202521
- Chief financial officerRhonda M. Chicko May 23, 2018 to Feb 4, 201922
- Chief operating officerKeith Woods Apr 29, 2025 to now23
- Chief operating officerEdward H. Myles Feb 15, 2022 to Mar 12, 202524
- Chief operating officerElan Ezickson May 23, 2018 to May 31, 201825
Board members and other officers (24)
- SVP and Head of ResearchMo Qatanani Jun 22, 2023 to now26
- Chief Commercial OfficerTracey Sacco Jun 22, 2023 to now27
- CHROCaryn Parlavecchio May 26, 2022 to now28
- Chief Medical OfficerJing L. Marantz Nov 15, 2022 to now29
- Head of ResearchGregory John Carven Jun 18, 2020 to Jun 21, 202230
- SVP, FinanceErin Moore Dec 20, 2019 to Mar 25, 202531
- Chief Scientific OfficerAlan J. Buckler May 23, 2018 to Feb 10, 202032
- Chief Medical OfficerYung H. Chyung May 23, 2018 to Feb 15, 202233
- Board memberJay T. Backstrom Feb 13, 2024 to Mar 12, 202534
- Board memberKatie Peng Feb 15, 2024 to now35
- Board memberRichard Brudnick Apr 10, 2023 to now36
- Board memberSrinivas Akkaraju Jul 28, 2022 to now37
- Board memberJoshua Reed Mar 18, 2021 to now38
- Board memberStuart A. Kingsley May 21, 2020 to Feb 3, 202139
- Board memberAkshay Vaishnaw May 23, 2019 to now40
- Board memberAmir Nashat May 23, 2018 to May 13, 202441
- Board memberDavid Hallal May 23, 2018 to now42
- Board memberJeffrey S. Flier May 23, 2018 to now43
- Board memberKristina Burow May 23, 2018 to now44
- Board memberMichael Gilman May 23, 2018 to now45
- Board memberNagesh K. Mahanthappa May 23, 2018 to Aug 10, 202118
- Board memberTimothy A. Springer May 23, 2018 to Sep 5, 201946
- Board memberEdward H. Myles Nov 21, 2018 to Jun 18, 202047
- General counselJunlin Ho Jun 25, 2021 to now48
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Scholar Rock Foreign Holdings, Inc. Delaware5
- Scholar Rock Germany GmbH Germany5
- Scholar Rock Ireland Limited Ireland5
- Scholar Rock Netherlands B.V. The Netherlands5
- Scholar Rock Securities Corporation Massachusetts5
- Scholar Rock Switzerland GmbH Switzerland5
- Scholar Rock U.S. Operations, Inc. Delaware5
- Scholar Rock, Inc. Delaware5
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Sep 15, 20268-K Regulation FD disclosure49
- Sep 14, 20268-K Regulation FD disclosure; Other events50
- Aug 6, 20268-K Results of operations51
- Aug 6, 20268-K Other events52
- Jun 5, 20268-K Shareholder vote53
- May 7, 20268-K Results of operations; Regulation FD disclosure54
- Mar 31, 20268-K Regulation FD disclosure; Other events55
- Mar 3, 20268-K Results of operations; Regulation FD disclosure56
- Mar 3, 20268-K Results of operations; Regulation FD disclosure57
- Jan 12, 20268-K Results of operations; Regulation FD disclosure; Other events58
- Dec 2, 20258-K Other events59
- Nov 14, 20258-K Results of operations; Regulation FD disclosure60
- Apr 29, 2025New chief executive David Hallal becomes CEO15
- Sep 22, 2022New chief executive Jay T. Backstrom becomes CEO16
- Jul 17, 2020New chief executive Stuart A. Kingsley becomes CEO17
- May 23, 2018New chief executive Nagesh K. Mahanthappa becomes CEO18
- Dec 31, 2016Founded Scholar Rock Holding Corp is founded2
Calendar
Coming up
- Nov 10, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported ($0.90) a share, on Nov 14, 2025.61
When it reported results
- Aug 6, 2026Reported quarterly or annual results51
- May 7, 2026Reported quarterly or annual results54
- Mar 3, 2026Reported quarterly or annual results56
- Mar 3, 2026Reported quarterly or annual results57
- Jan 12, 2026Reported quarterly or annual results58
- Nov 14, 2025Reported quarterly or annual results60
- Aug 6, 2025Reported quarterly or annual results62
- May 14, 2025Reported quarterly or annual results63
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
438 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 65 major events, 231 insider forms, 47 large holders, 75 other. The latest 20:
- Oct 1, 2026144 EDGAR
- Sep 25, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 23, 20264 OWNERSHIP DOCUMENT EDGAR
- Sep 15, 20268-K EDGAR
- Sep 14, 20268-K EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 2026424B5 EDGAR
- Jul 6, 2026144 EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jul 6, 20264 EDGAR
- Jul 1, 2026144 EDGAR
- Jul 1, 2026144 EDGAR
- Jul 1, 2026144 EDGAR
The 438 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
109 open-market trades by officers, directors and large owners since October 2021: 12 buys and 97 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 1, 2026 | FLIER JEFFREY S.Director | Sale | 3,053 | $53.88 | $164.5K | Form 4 |
| Jul 1, 2026 | Gilman MichaelDirector | Sale | 2,544 | $53.87 | $137.1K | Form 4 |
| Jul 1, 2026 | Burow KristinaDirector | Sale | 3,053 | $53.74 | $164.1K | Form 4 |
| Jul 1, 2026 | Reed JoshuaDirector | Sale | 3,053 | $53.74 | $164.1K | Form 4 |
| Jul 1, 2026 | Peng KatieDirector | Sale | 5,446 | $53.87 | $293.4K | Form 4 |
| Apr 16, 2026 | Woods KeithChief Operating Officer | Sale | 10,220 | $49.57 | $506.6K | Form 4 |
| Apr 16, 2026 | Vaishnaw AkshayPresident of R&D | Sale | 12,246 | $49.57 | $607.0K | Form 4 |
| Apr 16, 2026 | Sinha VikasChief Financial Officer | Sale | 10,410 | $49.57 | $516.0K | Form 4 |
| Apr 16, 2026 | Hallal DavidChief Executive Officer | Sale | 30,615 | $49.57 | $1.5M | Form 4 |
| Feb 23, 2026 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 8,484 | $47.07 | $399.3K | Form 4 |
| Feb 17, 2026 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 7,989 | $46.53 | $371.7K | Form 4 |
| Feb 17, 2026 | Parlavecchio CarynCHRO | Sale | 9,035 | $46.53 | $420.4K | Form 4 |
| Feb 17, 2026 | Ho JunlinGENERAL COUNSEL | Sale | 9,580 | $46.53 | $445.8K | Form 4 |
| Feb 17, 2026 | Marantz Jing L.CHIEF MEDICAL OFFICER | Sale | 4,157 | $46.53 | $193.4K | Form 4 |
| Jan 22, 2026 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 14,898 | $46.71 | $695.9K | Form 4 |
| Jan 16, 2026 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 8,406 | $44.48 | $373.9K | Form 4 |
| Jan 16, 2026 | Parlavecchio CarynCHRO | Sale | 6,600 | $44.48 | $293.6K | Form 4 |
| Jan 16, 2026 | Ho JunlinGENERAL COUNSEL | Sale | 8,016 | $44.48 | $356.6K | Form 4 |
| Jan 16, 2026 | Marantz Jing L.CHIEF MEDICAL OFFICER | Sale | 5,798 | $44.48 | $257.9K | Form 4 |
| Jan 14, 2026 | Qatanani MoCHIEF SCIENTIFIC OFFICER | Sale | 13,112 | $45.20 | $592.7K | Form 4 |
All 109 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Redmile Group, LLCSCHEDULE 13G/A, 9 filings Feb 14, 2022 to Aug 14, 202664
- Invus Global Management, LLCSCHEDULE 13G/A, 3 filings Jul 29, 2024 to Aug 13, 202665
- PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G/A, 7 filings Feb 14, 2022 to May 15, 202666
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Nov 4, 2024 to Mar 27, 202667
- Wellington Management CompanySCHEDULE 13G, 1 filing Feb 10, 202668
- Samsara BioCapital, L.P.SCHEDULE 13D/A, 4 filings Feb 14, 2023 to Oct 7, 202569
- FMR LLCSCHEDULE 13G/A, 5 filings Feb 9, 2022 to Feb 12, 202570
- ORBIMED ADVISORS LLCSC 13G/A, 2 filings Feb 14, 2024 to Nov 14, 202471
- ARCH Venture Fund VIII, L.P.SC 13G/A, 1 filing Feb 14, 202472
- Artal International S.C.A.SC 13G/A, 4 filings Feb 11, 2022 to Feb 9, 202473
- Polaris Venture Partners VI, L.P.SC 13G/A, 3 filings Feb 11, 2022 to Feb 9, 202474
- BlackRockSC 13G, 3 filings Feb 3, 2022 to Jan 26, 202475
- BB BiotechSC 13G/A, 2 filings Feb 11, 2022 to Feb 14, 202376
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | David Hallal Chief Executive Officer and Chairman | 59 | $637.5K | $33.3M77 |
| 2025 | Jay Backstrom, M.D., M.P.H. Former President and Chief Executive Officer | $600.2K | $17.5M77 | |
| 2025 | Akshay Vaishnaw, M.D., Ph.D. President of R&D | 63 | $523.1K | $14.9M77 |
| 2025 | R. Keith Woods Chief Operating Officer | 58 | $523.1K | $12.9M77 |
| 2025 | Vikas Sinha Chief Financial Officer | 62 | $523.1K | $12.9M77 |
| 2024 | Jay Backstrom, M.D., M.P.H. Former President and Chief Executive Officer | $649.5K | $8.0M77 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Fmr LLC | 17,995,241 | $989.7M | 0.0% | +752,089 |
| Siren, L.L.C. | 9,575,013 | $526.6M | 10.7% | −1,250,000 |
| BlackRock, Inc. | 9,494,084 | $522.2M | 0.0% | +2,024,791 |
| Samsara Biocapital, LLC | 6,897,652 | $379.4M | 31.2% | No change |
| Wellington Management Group Llp | 6,727,085 | $370.0M | 0.1% | +9,430 |
| Orbis Allan Gray Ltd | 5,933,533 | $326.3M | 1.1% | +1,753,550 |
| Vanguard Capital Management LLC | 4,767,880 | $262.2M | 0.0% | +876,533 |
| State Street Corp | 4,728,681 | $260.1M | 0.0% | +697,364 |
| Redmile Group, LLC | 4,311,092 | $237.1M | 15.9% | −4,755,529 |
| Norges Bank | 2,769,910 | $152.3M | 0.0% | New |
| Geode Capital Management, LLC | 2,753,787 | $151.5M | 0.0% | +604,751 |
| Massachusetts Financial Services Co /ma/ | 2,607,348 | $143.4M | 0.0% | New |
| Bellevue Group AG | 2,449,547 | $134.7M | 2.8% | −1,135,026 |
| Jennison Associates LLC | 2,358,587 | $129.7M | 0.1% | −981,905 |
| Jupiter Topco LLC | 2,242,106 | $123.3M | 0.1% | New |
| Hood River Capital Management LLC | 2,224,788 | $122.4M | 0.9% | +175,109 |
| Driehaus Capital Management LLC | 2,205,618 | $121.3M | 0.7% | +285,385 |
| Eventide Asset Management, LLC | 2,111,410 | $116.1M | 1.6% | −85,975 |
| Polar Capital Holdings Plc | 1,878,580 | $103.3M | 0.3% | −105,048 |
| Holocene Advisors, LP | 1,755,978 | $96.6M | 0.2% | −134,949 |
| Adage Capital Partners Gp, L.l.c. | 1,731,402 | $95.2M | 0.1% | +1,031,402 |
| Morgan Stanley | 1,538,776 | $84.6M | 0.0% | +1,319,749 |
| Woodline Partners LP | 1,500,470 | $82.5M | 0.3% | No change |
| Goldman Sachs Group Inc | 1,411,477 | $77.6M | 0.0% | +12,494 |
| Capital World Investors | 1,160,409 | $63.8M | 0.0% | +31,657 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Scholar Rock Holding Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARScholar Rock Holding Corp1
- CIK0001727196
- Employer ID (EIN)82-37504356
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company6
- Incorporated inDelaware6
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address301 Binney Street, 3Rd Floor, Cambridge, MA 021421
- Phone857-259-38601
- Shares outstanding121,785,282 as of Aug 3, 202614
- Public float$2.6B as of Jun 30, 20256
- AuditorDeloitte & Touche LLP, Boston, PCAOB ID 34; no auditor attestation of internal control over financial reporting6
- On EDGAR sinceJan 8, 20181
- Filings648 in all: 4 (281), 8-K (106), SC 13G/A (45), 3 (36), 144 (34), 10-Q (25), SC 13G (13), 424B5 (11)1
All 41 form types
S-8 (11), SCHEDULE 13G/A (10), 10-K (8), DEF 14A (8), DEFA14A (7), CORRESP (6), ARS (4), EFFECT (4), UPLOAD (4), 8-K/A (3), CT ORDER (3), 4/A (2), DRS/A (2), FWP (2), S-1/A (2), S-3 (2), S-3ASR (2), SC 13D/A (2), 424B4 (1), 5 (1), 8-A12B (1), CERT (1), D (1), DRS (1), DRSLTR (1), POS AM (1), POSASR (1), PRE 14A (1), S-1 (1), S-3MEF (1), SC 13D (1), SCHEDULE 13D/A (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 3, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 22, 2026
Latest 8-K (8-K) Sep 15, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock | SRRK | Nasdaq |
From the cover page of the 10-K filed Mar 3, 2026 (Section 12(b) of the Exchange Act).6
Risk factors and legal proceedings
The risks Scholar Rock Holding Corp names in Item 1A of its 10-K filed Mar 3, 2026: 69 risks under these headings, as written.6
- Risks Related to Product Development, Regulatory Approval and Commercialization
- We have never commercialized a product and are in the process of building and scaling our business for potential commercialization of apitegromab in the United States and Europe, including building our compliance, medical affairs and commercial organizations, which, if we are not able to do so successfully could negatively impact our business, including the potential for a successful commercialization of apitegromab.
- Changes or disruptions at the FDA and other government agencies caused by funding cuts, government shutdowns, personnel reductions, substantial changes in leadership and policy, or other changes or disruptions to these agencies’ operations could prevent these agencies from performing functions on which the operation of our business relies, including the timely review and potential approval of our BLA, when resubmitted, and any such disruptions and changes could negatively impact our business.
- Product development involves a lengthy and expensive process, with an uncertain outcome. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of apitegromab, SRK-181, SRK-439, or any future product candidates. Many of the factors that cause, or lead to, a delay in the initiation or completion of clinical trials may also ultimately lead to the denial of regulatory approval or limit market acceptance of our product candidates.
- Our clinical development strategy depends on the continued use and availability of certain third-party approved drug therapies.
- The results or success of preclinical studies and early-stage clinical trials of our product candidates may not be predictive of future results or replicated in later preclinical studies or clinical trials of our product candidates in the same indications or other indications.
- Interim, initial, or preliminary results from our clinical trials that we announce or publish from time to time may change (e.g., from positive safety or efficacy results to poor or negative safety or efficacy results) as more patient data become available and are subject to additional audit, validation and verification procedures that could result in material changes in the final data.
- If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
- We rely on third parties to conduct our clinical trials and certain aspects of our preclinical studies. If these third parties do not successfully carry out their contractual duties or meet expected deadlines or comply with legal and regulatory requirements, we may be delayed or unable to receive regulatory approval of or commercialize apitegromab, SRK-181, SRK-439 or any future product candidates, and our business could be materially harmed.
- We have received Orphan Drug designation from the FDA for apitegromab for the treatment of SMA and the EC granted Orphan Medicinal Product designation to apitegromab for the treatment of SMA. We may seek Orphan Drug designation from regulatory authorities in other jurisdictions for apitegromab. We may not receive the requested designation or we may be unable to realize the benefits associated with Orphan Drug designation, including the potential for market exclusivity.
- We have received Rare Pediatric Disease designation for apitegromab for the treatment of SMA. However, a marketing application for apitegromab, if approved, may not meet the eligibility criteria for a rare pediatric disease priority review voucher.
- We have received Fast Track designation from the FDA and PRIME designation from the EMA for apitegromab for the treatment of SMA. We may seek Fast Track designation or Breakthrough Therapy designation from the FDA or PRIME designation from the EMA for certain of our current and future product candidates, and we may not be successful in receiving such designations, or if received, such designation may not actually lead to a faster development or regulatory review or approval process.
The other 58 risks
- Receiving and maintaining regulatory approval of apitegromab in one jurisdiction does not mean that we will be successful in receiving or maintaining regulatory approval of apitegromab in other jurisdictions.
- Even if we receive regulatory approval of apitegromab, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with apitegromab.
- Even if apitegromab receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
- If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market apitegromab in the EU, we may not be successful in commercializing apitegromab if and when it is approved.
- Competing therapies may exist or could emerge that adversely affect the amount of revenue we are able to generate from the sale of apitegromab, if approved, or any of our future product candidates, if successfully developed and approved.
- Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to develop our product pipeline and receive regulatory approvals or commercialize these programs on a timely basis or at all, which would have an adverse effect on our business.
- Risks Related to Our Business and Operations
- Because we rely on a limited number of third-party manufacturing and supply partners, our supply of research and development, preclinical and clinical development materials, and, if approved, commercial materials, may become limited or interrupted or may not be of satisfactory quantity or quality.
- Our reliance on third parties, such as manufacturers, third-party logistics providers, specialty distributors, specialty pharmacies, and patient service providers, may subject us to risks and may cause us to undertake substantial obligations, including financial obligations.
- We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, ongoing military conflicts, new regulatory activities and economic policies, high inflation and interest rates and the imposition of tariffs, other trade barriers and retaliatory countermeasures, any of which could have a material adverse effect on our business, financial condition and results of operations.
- We will need to continue to grow our organization in certain areas, including our personnel, systems and relationships with third parties, in order to develop and potentially commercialize our product candidates, and we may experience difficulties in managing this growth.
- Our executives and highly skilled technical and managerial personnel are critical to our business. If we have transition in management, lose key personnel, or if we fail to recruit additional highly skilled personnel, our ability to further develop and potentially commercialize apitegromab, SRK-181 and SRK-439 and identify and develop new or next generation product candidates may be impaired.
- Our internal computer systems, or those used by our contract research organizations, or other contractors or consultants, may fail or suffer security breaches, incidents or compromises.
- Our employees, independent contractors, consultants, commercial partners, vendors and distributors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.
- Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business.
- Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
- Failure to comply with health care privacy and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.
- Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data.
- Additional laws and regulations governing international operations, including certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations, could negatively impact or restrict our operations.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
- If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.
- Our current laboratory operations are concentrated in one location, and we or the third parties upon whom we depend, including our clinical trial sites and the manufacturing facilities of our third-party contract manufacturers, may experience business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster, including earthquakes, outbreak of disease or other natural disasters.
- Coverage and reimbursement may be limited or unavailable in certain market segments for apitegromab, if approved, which could make it difficult for us to sell apitegromab profitably.
- EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for apitegromab in the EU Member States. Also, unfavorable pricing and reimbursement decisions in the EU could delay or limit commercialization of apitegromab, if approved, and materially adversely affect our business, financial condition and results of operations.
- We may seek to enter into collaborations in the future with third parties, including for apitegromab, SRK-181, SRK-439 or potential product candidates. If we are unable to enter into such collaborations, or if these collaborations are not successful, our business could be adversely affected.
- Risks Related to Our Intellectual Property
- Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection.
- We depend on intellectual property licensed from third parties. Failure to comply with our obligations under any of these licenses or termination of any of these licenses could result in the loss of significant rights, which would harm our business.
- We may not be successful in obtaining or maintaining necessary rights to develop any future product candidates on acceptable terms.
- Changes in patent law in the U.S. and in ex-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
- Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.
- We may incur substantial costs as a result of litigation or other proceedings relating to our patents or the patents of our licensors, and we may be unable to protect our rights to our products and technology.
- Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.
- We have limited foreign intellectual property rights and may not be able to protect our intellectual property rights throughout the world.
- Patent terms may result in inadequate protection for our product candidates, and we may be unable to obtain patent term extensions and data exclusivity for our product candidates, resulting in material harm to our business.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- Third parties may assert that our employees or consultants have wrongfully used, disclosed, or misappropriated their confidential information or trade secrets.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- Risks Related to Our Financial Condition and Capital Requirements
- We have incurred net losses in every year since our inception and anticipate that we will continue to incur net losses in the future.
- We will require additional capital to fund our operations and if we fail to obtain necessary capital, we will not be able to complete the development and commercialization of apitegromab, SRK-181, SRK-439 and any future product candidates.
- Changes in tax law could adversely affect our business and financial condition.
- Our ability to use our net operating loss carryforwards and certain tax credit carryforwards may be subject to limitation.
- Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our current and projected business operations and our financial condition and results of operations.
- Our current investment policy focuses on preservation of capital. However, we could recognize losses on securities held in our investment portfolio, particularly if interest rates increase or economic and market conditions deteriorate.
- The terms of our loan agreements place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
- Risks Related to Our Common Stock
- The price of our stock is volatile, and you could lose all or part of your investment.
- We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.
- The members of our board of directors, management, and their affiliates, own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.
- We no longer qualify as a smaller reporting company as of January 1, 2026, which will increase our costs and demands on management.
- We expect to continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.
- If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
- We have broad discretion in the use of our existing cash, cash equivalents and marketable securities and may not use them effectively.
- Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.
- If securities or industry analysts publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
- We may be subject to securities litigation, which is expensive and could divert management attention.
- Our amended and restated bylaws contain certain exclusive forum provisions requiring that substantially all disputes between us and our stockholders be resolved in certain judicial forums, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.
- We have issued a substantial number of warrants and equity awards from our equity plans which are exercisable into shares of our common stock which could result in substantial dilution to the ownership interests of our existing stockholders.
- Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
- The sale or issuance of our common stock to, or through, Jefferies may cause significant dilution and the sale of the shares of common stock acquired by Jefferies, or the perception that such sales may occur, could cause the price of our common stock to fall.
Legal proceedings
From time to time, we are subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this Annual Report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
The opening of Item 3, Legal Proceedings.6
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3Yahoo FinanceSRRK quote
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19SEC EDGARAkshay Vaishnaw, President
- 20SEC EDGARVikas Sinha, Chief financial officer
- 21
- 22
- 23SEC EDGARKeith Woods, Chief operating officer
- 24
- 25
- 26
- 27
- 28SEC EDGARCaryn Parlavecchio, CHRO
- 29
- 30
- 31SEC EDGARErin Moore, SVP, Finance
- 32
- 33
- 34SEC EDGARJay T. Backstrom, Board member
- 35SEC EDGARKatie Peng, Board member
- 36SEC EDGARRichard Brudnick, Board member
- 37SEC EDGARSrinivas Akkaraju, Board member
- 38SEC EDGARJoshua Reed, Board member
- 39SEC EDGARStuart A. Kingsley, Board member
- 40SEC EDGARAkshay Vaishnaw, Board member
- 41SEC EDGARAmir Nashat, Board member
- 42SEC EDGARDavid Hallal, Board member
- 43SEC EDGARJeffrey S. Flier, Board member
- 44SEC EDGARKristina Burow, Board member
- 45SEC EDGARMichael Gilman, Board member
- 46SEC EDGARTimothy A. Springer, Board member
- 47SEC EDGAREdward H. Myles, Board member
- 48SEC EDGARJunlin Ho, General counsel
- 49SEC EDGARRegulation FD disclosure
- 50
- 51SEC EDGARResults of operations
- 52SEC EDGAROther events
- 53SEC EDGARShareholder vote
- 54
- 55
- 56
- 57
- 58
- 59SEC EDGAROther events
- 60
- 61NasdaqNasdaq calendar
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77